|
I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers Clinical research trials and I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers. I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers clinical trial. Test subjects typically obtain the finest healthcare available for their I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "I" Clinical Trials Conditions > I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers  I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers
I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers
For Condition: Healthy,Mental Disorder,Obsessive Compulsive Disorder,Schizophrenia,Tourette Syndrome
Status: Completed
Sponsor(s): National Institute of Mental Health (NIMH) ,
Synopsis: Abnormalities in the re-uptake of dopamine and serotonin have been described in various neuropsychiatric disorders and substance abuse. [I-123] Beta-CIT is a recently developed radioligand for SPECT imaging of dopamine and serotonin transporters. [I-123]Beta-CIT SPECT has been used at the SPECT-lab of the Clinical Brain Disorders Branch in over fifty subjects without adverse events. Due to the trace concentrations used, a pharmacological effect of Beta-CIT is unlikely and has not been observed. The purpose of this study is to use Beta-CIT and SPECT to study the expression of dopamine and serotonin transporters in vivo in normal controls and various patient populations to address hypothesized abnormalities of the transporters in different disorders and to understand the effects of genetic variations in the genes of these transporters on their in vivo expression.
Details: Abnormalities in the re-uptake of dopamine and serotonin have been described in various neuropsychiatric disorders and substance abuse. [I-123] Beta-CIT is a recently developed radioligand for SPECT imaging of dopamine and serotonin transporters. [I-123]Beta-CIT SPECT has been used at the SPECT-Lab of the Clinical Brain Disorders Branch in over fifty subjects without adverse events. Due to the trace concentrations used, a pharmacological effect of Beta-CIT is unlikely and has not been observed. The purpose of this study is to use Beta-CIT and SPECT to study the expression of dopamine and serotonin transporters in vivo in normal controls and various patient populations to address hypothesized abnormalities of the transporters in different disorders and to understand the effects of genetic variations in the genes of these transporters on their in vivo expression.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: No Axis I or Axis II diagnoses. EXCLUSION CRITERIA FOR ALL SUBJECTS: If the pregnancy test is positive or if the woman has reason to believe she might be pregnant, she will be excluded from this study. Women who are breastfeeding will be excluded from this study to avoid unwarranted risk to their children. Subjects with a prior reaction to iodine, iodine compounds, or shellfish will be excluded from this study. Subjects with a history of thyroid disease or dysfunction will be excluded from this study. Subjects with a history of recent substance abuse will be excluded from this study. Subjects with metal objects in their bodies as specified in our MRI protocol (91-M-0124) will be excluded from this study. If a structural abnormality of the brain is detected on MRI, subjects will be excluded from the study. EXCLUSION CRITERIA FOR NORMAL CONTROLS: Subjects with an Axis I or Axis II disorder will be excluded. Subjects with concomitant medical or neurological disorders which require ongoing medication, or which may affect the central nervous system will be excluded.
Total Enrollment: 112
Location and Contact Information:
National Institute of Mental Health (NIMH)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 980094; 98-M-0094
Study Start Date: May 7, 1998
Record last reviewed: May 6, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001771
Other Tourette Syndrome Studies:
1. The Assessment of a weight-gain agent for the Treatment of Olanzapine-Associated Anti-obesity Agent in Patients with Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, and Bipolar I Disorder
2. I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers
3. Cognitive Behavioral Therapy for Post-Traumatic Stress Disorder in Individuals with Severe Mental Illness
4. Genetic Aspects of Neurologic and Psychiatric Disorders
5. Inpatient Evaluation of Adults with Schizophrenia
Related Studies:
Other Tourette Syndrome Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers
|
|
|
|
|
|
|
|
